文献速递腹部CTMR

CT/MRI LI-RADS v2018 在非肝硬化脂肪性肝病中的诊断效能

Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease.
PubMed 文献 · Eur Radiol · 2024-07-01

本回顾性研究纳入77例非肝硬化脂肪性肝病患者的119个观察灶,评估CT/MRI LI-RADS v2018的诊断效能。LR-5诊断HCC的敏感度79-83%、特异度91-97%、准确率89-92%,LR-5/LR-M/LR-TIV联合诊断恶性肿瘤的敏感度86-89%、特异度85-96%。作者认为尽管CT上非周边廓清比例较低且HCC与肝细胞腺瘤影像重叠,LI-RADS仍可作为有效评估工具。

要点

  • LR-5诊断HCC的PPV为75-88%,特异度91-97%,准确率89-92%。
  • CT上仅59-65%的HCC显示非周边廓清,MRI为67-83%,但几乎所有HCC均有强化包膜。
  • LR-5最常见的假阳性为肝细胞腺瘤。

核心结论

  • 尽管存在CT上非周边廓清比例较低及HCC与肝细胞腺瘤影像特征重叠等挑战,LI-RADS可能作为评估非肝硬化脂肪性肝病局灶性肝脏病变的有效工具。

研究设计与样本

  • IRB批准的回顾性研究,纳入2010至2023年77例成人患者(36女,41男;中位年龄64岁)的119个观察灶,均有SLD无肝硬化的组织病理学证据;3名腹部放射科医师盲法评估LI-RADS。

关键影像表现/征象

  • CT上仅59-65%的HCC显示非周边廓清,MRI为67-83%,但几乎所有HCC均有强化包膜。
  • LR-5最常见的假阳性为肝细胞腺瘤。

诊断标准与关键数值

  • LR-5诊断HCC的PPV为75-88%,敏感度79-83%,特异度91-97%,准确率89-92%。
  • LR-5、LR-M或LR-TIV联合诊断恶性肿瘤的敏感度86-89%,特异度85-96%,准确率86-93%。
  • HCC的PPV:LR-1为0-0%,LR-2为0-0%,LR-3为0-7%,LR-4为11-20%,LR-5为75-88%,LR-M为0-8%,LR-TIV为50-75%。
  • LR-5诊断HCC的PPV和准确率不受检查方式影响。
  • 主要特征间读者间一致性为0.667至0.830,最终分类的读者间一致性为0.766。

临床应用与阅片要点

  • 在非肝硬化脂肪性肝病患者中,LR-5分类对HCC具有高特异度(91-97%)。
  • CT上非周边廓清比例较低(59-65% vs MRI 67-83%),但几乎所有HCC有强化包膜。
  • 需注意LR-5假阳性最常见为肝细胞腺瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the performance of computed tomography (CT)/magnetic resonance imaging (MRI) Liver Imaging Reporting and Data System (LI-RADS) among patients with non-cirrhotic steatotic liver disease (SLD).

MATERIALS AND METHODS: This IRB-approved, retrospective study included 119 observations from 77 adult patients (36 women, 41 men; median 64 years) who underwent liver CT or MRI from 2010 to 2023. All patients had histopathologic evidence of SLD without cirrhosis. Three board-certified abdominal radiologists blinded to tissue diagnosis and imaging follow-up assessed observations with LI-RADS. The positive predictive value (PPV), sensitivity, specificity, accuracy, and inter-reader agreement were calculated.

RESULTS: Seventy-five observations (63%) were benign and 44 (37%) were malignant. PPV for hepatocellular carcinoma (HCC) was 0-0% for LR-1, 0-0% for LR-2, 0-7% for LR-3, 11-20% for LR-4, 75-88% for LR-5, 0-8% for LR-M, and 50-75% for LR-TIV. For LR-5 in identifying HCC, sensitivity was 79-83%, specificity was 91-97%, and accuracy was 89-92%. For composite categories of LR-5, LR-M, or LR-TIV in identifying malignancy, sensitivity was 86-89%, specificity was 85-96%, and accuracy was 86-93%. The most common false positives for LR-5 were hepatocellular adenomas. Only 59-65% of HCCs showed non-peripheral washout at CT versus 67-83% at MRI, though nearly all had an enhancing capsule. PPV and accuracy of LR-5 for HCC did not differ by modality. Inter-reader agreement for major features ranged from 0.667 to 0.830 and was 0.766 for the final category.

CONCLUSION: Despite challenges such as the lower prevalence of non-peripheral washout at CT and overlapping imaging features between HCC and hepatocellular adenomas, LI-RADS may serve as an effective tool in assessing focal liver lesions in SLD.

CLINICAL RELEVANCE STATEMENT: LI-RADS in non-cirrhotic steatotic liver disease can effectively diagnose hepatocellular carcinoma and malignancy at computed tomography and magnetic resonance imaging, thereby guiding clinical management decisions and expediting patient care pathways.

KEY POINTS: Performance of LI-RADS is unknown in non-cirrhotic patients with steatotic liver disease. LI-RADS 5 category showed a high pooled specificity of 91-97% for hepatocellular carcinoma. LI-RADS can non-invasively risk stratify focal liver observations in non-cirrhotic patients with steatotic liver disease.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Cao J, Shon A, Yoon L, et al. Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease. Eur Radiol. 2024. PMID: 38951191. doi:10.1007/s00330-024-10846-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。